ArsenalBio is a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors.

ArsenalBio is on a mission to discover, develop and commercialize curative immune cell therapies.

ArsenalBio was founded in 2019 by Ken Drazan. The company is headquartered in South San Francisco , CA.


ArsenalBio's full-stack R&D engine generates multifunctional T cell medicines, enabled by precise and specific CRISPR insertion of large synthetic DNA sequences.


ArsenalBio is building the industry’s largest DNA library of therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions.


ArsenalBio's lead program AB-1015, an ovarian cancer candidate for which FDA IND clearance and first patient dosing are targeted for later this year. The company also has candidates in early development for kidney, prostate, and other cancer indications.


ArsenalBio is backed by Softbank Vision Fund 2, Bristol-Myers Squibb Company, Parker Institute for Cancer Immunotherapy (PICI), Westlake Village BioPartners, Byers Capital, Emerson Collective Investments, Green Sands, Hitachi Ventures, Sixth Street, and others. The company raised $220M in Series B round on Sep 06, 2022. This brings ArsenalBio's total funding to $305.8M to date.



  • Year founded: 2019
  • Funding Info: $305.8M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: South San Francisco
  • State: California
  • Country: United States
Related businesses